May 22, 2019
Breakthrough will bring together unique experts in the field, including innovators, scientists, and technology specialists, all to discuss better solutions for cancer care, writes ASCO president-elect Dr. Howard A. "Skip" Burris.
May 20, 2019
Health Equity Committee chair Dr. William D. Tap highlights the recent work and forward momentum of ASCO's efforts to achieve health care equity for all through improved access to and quality of care.
May 20, 2019
The Impact of Utilization Management on Patients and Practices: A Conversation with Dr. Jeffery Ward
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
May 17, 2019
To help you get the most out of #ASCO19, I'm sharing a vlog on networking (it's not as scary as you think!) and strategies for organizing your schedule and maximizing your face time with the people you want to meet.
Subscribe to this column
ASCO Commentary provides an interactive platform for ASCO’s organizational leadership and senior staff to connect directly to ASCO’s membership and the wider oncology community.
Feb 21, 2018
Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.
Oct 28, 2016
Dr. Richard L. Schilsky outlines the Society's Target Agent and Profiling Utilization Registry (TAPUR) Study and similar international protocols. A global data sharing platform could greatly accelerate our ability to learn about new uses for currently approved targeted anticancer drugs.
Nov 02, 2015
Chief Medical Officer Dr. Richard L. Schilsky answers your questions about this exciting new opportunity in health care policy and advocacy.
Oct 26, 2015
Personalized cancer care is not a new concept, but its application has been enabled and enhanced by a far greater understanding of the biological underpinnings of cancer than ever existed before.
Nov 12, 2014
By Richard L. Schilsky, MD, FASCO, Chief Medical Officer of ASCO. During the past six weeks I’ve had the opportunity to attend cancer meetings in four countries on three continents. In September, I represented ASCO at the annual meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen,...
Feb 06, 2014
Meaningful Progress Against Gastric, Pancreatic, and Colorectal Cancers Reported at the 2014 Gastrointestinal Cancers Symposium
By Richard L. Schilsky, MD, FASCO, Chief Medical Officer of ASCO. I’ve been a regular attendee of the Gastrointestinal Cancers Symposium since it began 11 years ago. This year’s meeting was among the very best with record attendance, superb educational talks and keynote lectures, multidisciplinary...